when do you start seeing weight loss with semaglutide Before and After: Real Results Semaglutide Weight Loss Program Seattle

Consulting a clinician before undergoing both treatments is highly recommended to ensure safe, personalised care

As per estimates, the prevalence of MAFLD among adults in general ranges from 25 to 30%, while the occurrence of underlying nonalcoholic steatohepatitis (NASH) is estimated to be between 3% and 6%

Obesity, defined as a body mass index (BMI) of 30, is a major public health issue with significant economic and societal impacts

If you have a history of gallbladder disease, we may not be able to treat you since semaglutide can lead to an increase in gallstones

Semaglutide (Ozempic) was approved in December 2017 for adults with type 2 diabetes, with the brand name Wegovy approved in 2021 for chronic weight management

Key results published in The Lancet Psychiatry: Both medications were safe & effective adjuncts Quetiapine was superior to lithium in improving symptoms over one year Quetiapine was more cost-effective for services & society Patients reported better functioning & quality of life Read more: Study site: Blog: Paper: Register for the free webinar (6 Oct): #DifficultToTreatDepression #TreatmentResistantDepression #Prescribing #MentalHealthResearch To view or add a comment, sign in For prescribers: The LQD study tested lithium vs quetiapine augmentation for treatment-resistant depression